InvestorsHub Logo
Followers 17
Posts 10845
Boards Moderated 0
Alias Born 03/11/2017

Re: None

Tuesday, 06/27/2017 5:10:14 PM

Tuesday, June 27, 2017 5:10:14 PM

Post# of 44784
Excerpt From Pluristem's Feb 13,2017 Press Release !



• Enrollment in Phase I Hematologic Indication of PLX-R18
In the first quarter of 2017, Pluristem expects to initiate patient enrollment in its FDA-cleared, open-label Phase I trial of PLX-R18 to treat incomplete engraftment of hematopoietic cell transplant. Data will be available on an ongoing basis as this is an open label study.



http://www.pluristem.com/wp-content/uploads/2017/02/ShareholderLetter_final.pdf